PSMA Protein, Human, Recombinant (His & Avi), Biotinylated

Copy Product Info

Catalog No. TMPY-06960

PSMA Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with His and Avi tag. The predicted molecular weight is 82.72 kDa and the accession number is NP_004467.1.

PSMA Protein, Human, Recombinant (His & Avi), Biotinylated

Copy Product Info

Catalog No. TMPY-06960

Pack Size	Price	USA Warehouse	Global Warehouse
5 μg	$215	7-10 days	7-10 days
10 μg	$359	7-10 days	7-10 days
20 μg	$600	7-10 days	7-10 days
50 μg	$939	7-10 days	7-10 days
100 μg	$1,580	7-10 days	7-10 days

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse [1-2 days] Global Warehouse [5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Resource Download

User Guide of Recombinant Proteins

Product Information

Biological Activity	Immobilized Anti-PSMA Antibody at 2 μg/mL (100 μL/well) can bind PSMA Protein, Human, Recombinant (His & Avi), Biotinylated, the EC50 is 90-270 ng/mL.
Description	PSMA Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with His and Avi tag. The predicted molecular weight is 82.72 kDa and the accession number is NP_004467.1.
Species	Human
Expression System	HEK293 Cells
Tag	N-Avi-His
Accession Number	NP_004467.1
Synonyms	PSMA,PSM,NAALAdase,NAALAD1,mGCP,GCPII,GCP2,FOLH,folate hydrolase (prostate-specific membrane antigen) 1,FGCP
Construction	A DNA sequence encoding the Human FOLH1 (NP_004467.1) (Lys44-Ala750) was expressed with a N-terminal polyhistidine tagged AVI tag at the C-terminus. The expressed protein was biotinylated in vivo by the Biotin-Protein ligase (BirA enzyme) which is co-expressed. Predicted N terminal: Gly
Protein Purity	≥ 95 % as determined by SDS-PAGE. ≥ 95 % as determined by SEC-HPLC.
Molecular Weight	82.31 kDa (predicted); 104.1 kDa (reducing conditions due to glycosylation)
Endotoxin	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation	Lyophilized from sterile 0.9 mM CaCl2, 0.5 mM MgCl2-6H2O, 2.7 mM KCl, 1.5 mM KH2PO4, 137.9 mM NaCl, 8.1 mM NA2HPO4-7H2O, 0.5 mM ZnCl2, pH 7.2. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
Reconstitution	A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
Stability & Storage	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.
Research Background	Glutamate carboxypeptidase 2, also known as Glutamate carboxypeptidase II, Membrane glutamate carboxypeptidase, Prostate-specific membrane antigen, GCPII, PSMA, FOLH1, and NAALAD1, is a single-pass type II membrane protein which belongs to thepeptidase M28 family and M28B subfamily. FOLH1 is highly expressed in prostate epithelium. It is detected in urinary bladder, kidney, testis, ovary, fallopian tube, breast, adrenal gland, liver, esophagus, stomach, small intestine, colon, brain (at protein level), and the capillary endothelium of a variety of tumors. FOLH1 has both folate hydrolase and N-acetylated alpha linked acidic dipeptidase (NAALADase) activity. It has a preference for tri-alpha-glutamate peptides. Genetic variation in FOLH1 may be associated with low folate levels and consequent hyperhomocysteinemia. This condition can result in increased risk of cardiovascular disease, neural tube defects, and cognitive deficits. FOLH1 also shows a promising role in directed imaging and therapy of recurrent or metastatic disease.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy